Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proteinase K subfamily of the proprotein convertase family, which can combine with low-density lipoprotein receptor (LDLR), and inhibit the repeated use of LDLR, resulting in a decrease in LDLR on the surface of liver cells, an increase in LDL levels in peripheral blood and a series of pathophysiological processes such as abnormal blood lipid metabolism. Current studies have shown that PCSK9 has a certain correlation with myocardial infarction, and may regulate the occurrence and development of myocardial infarction through a way independent of low-density lipoprotein cholesterol (LDLC). This article will review the research progress of PCSK9 and myocardial infarction.